FDA ad­vi­sors vote 6-4 against Amy­lyx's ALS drug, fur­ther dim­ming its hope for reg­u­la­to­ry suc­cess

In a marathon hear­ing Wednes­day, out­side FDA ad­vi­sors rec­om­mend­ed to the agency that a sin­gle ran­dom­ized study did not pro­vide con­clu­sive proof over whether an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER